Maxacalcitol (trade name Oxarol) is a vitamin D<sub>3</sub> analog and vitamin D receptor activator (VDRA). As a pharmaceutical drug, it is used as an injection to treat secondary hyperparathyroidism resulting from hemodialysis and as a topical ointment for psoriasis.
It was approved for use in Japan in 2010 and in Taiwan in 2018.